Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesOphthalmology/OptometryUnitedHealthcare Encelto Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentUnitedHealthcarePolicy CSOH2026D0137.B

    Encelto (Revakinagene Taroretcel-Lwey) for Ohio Only

    Customize your policy alerts

    Sign up for UnitedHealthcare Policy CSOH2026D0137.B alerts

    Get alerted when Policy CSOH2026D0137.B changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    UnitedHealthcare Community Plan medical benefit drug policy governing coverage of Encelto for adults with idiopathic macular telangiectasia type 2 in Ohio, subject to medical-necessity criteria, prior authorization, dosing limits, and applicable Ohio requirements.

    Policy Summary
    PayerUnitedHealthcare
    PolicyEncelto (Revakinagene Taroretcel-Lwey) for Ohio Only
    Policy CodePolicy CSOH2026D0137.B
    Change TypeAdministrative/reference update
    Effective DateOctober 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with records confirming MacTel type 2 in at least one eye and documenting ophthalmologist prescribing, FDA-approved dosing, and retinal monitoring.
    SourceLink
    POLICY UPDATE CHANGES

    The References section was updated to reflect the most current information, and the prior policy version was archived.

    1 per eyeMaximum lifetime treatment limit
    60 daysMaximum authorization duration
    18+ yearsMinimum patient age
    J3403Listed Encelto implant code

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    OhioPolicy jurisdiction

    Covered Initial Therapy Criteria

    Covered initial therapy criteria

    Encelto is proven and medically necessary when all of the following criteria are met.

    Patient and diagnosis

    • The patient is at least 18 years of age.Age ≥ 18 years
    • Medical records, such as chart notes, confirm a diagnosis of non-proliferative macular telangiectasia type 2 (MacTel) in at least one eye.Diagnosis in ≥ 1 eye

      Submit the supporting medical records.

    Monitoring and provider requirements

    • The patient will be monitored for signs and symptoms of retinal tears and/or retinal detachment.

      Monitoring includes acute onset of flashing lights, floaters, and/or loss of visual acuity.

    • Encelto is prescribed by an ophthalmologist.
    • Dosing is in accordance with U.S. Food and Drug Administration (FDA)-approved labeling.

    Treatment and authorization limits

    • Treatment is limited to one treatment per eye per lifetime.1 treatment per eye per lifetime
    • Authorization is issued for no longer than 60 days from approval.≤ 60 days from approval

    Applicable Codes

    Applicable Procedure/Drug CodeHCPCS
    J3403Revakinagene taroretcel-lwey, per implant
    Diagnosis CodesICD-10
    H35.071 H35.072Retinal telangiectasis, right eye
    H35.073Retinal telangiectasis, bilateral
    H35.079Retinal telangiectasis, unspecified eye

    Authorization and Documentation Requirements

    Prior Authorization

    Obtain prior authorization for Encelto

    Prior authorization is required for Encelto coverage under the stated medical-necessity criteria. Authorization may be issued for no more than one treatment per eye per lifetime and for no longer than 60 days from approval.

    Documentation Required

    Document non-proliferative MacTel type 2

    Submit medical records, such as chart notes, confirming a diagnosis of non-proliferative macular telangiectasia type 2 (MacTel) in at least one eye.

    Documentation Required

    Document retinal tear and detachment monitoring

    Document that the patient will be monitored for signs and symptoms of retinal tears and/or retinal detachment. Include warning symptoms such as acute onset of flashing lights, floaters, and/or loss of visual acuity.

    Condition Overview

    Macular telangiectasia type 2 (MacTel) is a neurodegenerative metabolic disorder affecting the macular blood vessels and photoreceptors. In MacTel type 2, enlarged macular blood vessels leak fluid, causing swelling and scarring that may lead to vision loss. New blood vessels may also grow beneath the macula, further damaging photoreceptors and worsening vision loss.

    Key Terms

    Macular telangiectasia type 2 (MacTel)
    DefinitionThe most common type of macular telangiectasia; a neurodegenerative metabolic disorder affecting the macular blood vessels and photoreceptors.
    Vascular changesBlood vessels in the macula become enlarged and leak fluid, causing swelling and scarring.
    Potential complicationsNew blood vessels may grow beneath the macula, further damaging macular photoreceptors and worsening vision loss.
    Clinical populationOccurs most often in middle-aged adults; men and women are equally affected.
    Encelto
    Product definitionAn allogeneic encapsulated cell-based gene therapy indicated for adults with idiopathic MacTel.
    Policy Summary
    PayerUnitedHealthcare
    PolicyEncelto (Revakinagene Taroretcel-Lwey) for Ohio Only
    Policy CodePolicy CSOH2026D0137.B
    Change TypeAdministrative/reference update
    Effective DateOctober 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with records confirming MacTel type 2 in at least one eye and documenting ophthalmologist prescribing, FDA-approved dosing, and retinal monitoring.
    SourceLink
    On This Page
    Covered Initial Therapy CriteriaApplicable CodesAuthorization and Documentation RequirementsCondition OverviewKey Terms
    Documentation Required

    Verify ophthalmologist prescribing and FDA-approved dosing

    Document that Encelto is prescribed by an ophthalmologist and that dosing is in accordance with U.S. Food and Drug Administration (FDA)-approved labeling.

    Denial Risk

    Avoid clinical-criteria denial

    Coverage may be denied if the patient is younger than 18, the medical records do not confirm non-proliferative MacTel type 2 in at least one eye, the drug is not prescribed by an ophthalmologist, dosing does not follow FDA-approved labeling, or the required retinal tear and retinal detachment monitoring is not planned.

    Denial Risk

    Stay within treatment and authorization limits

    Coverage may be denied for treatment exceeding one treatment per eye per lifetime or for an authorization request exceeding 60 days from approval.

    Implant compositionThe implant contains approximately 200,000 to 440,000 retinal pigment epithelial cells.
    AdministrationAdministered through a single surgical procedure performed by a qualified ophthalmologist, with the implant placed into the eye.
    Secreted factorThe implant secretes recombinant human ciliary neurotrophic factor (rhCNTF).
    Mechanism-related descriptionExogenous CNTF is thought to initially target Müller glia and trigger signaling events that may promote photoreceptor survival; the mechanism of action is not completely understood.